Octreotide: Difference between revisions
Ostermayer (talk | contribs) (Created page with "==Administration== *Type: Octapeptide *Dosage Forms: *Routes of Administration: IV, IM *Common Trade Names: Sandostatin, Sandostatin LAR ==Adult Dosing== ==Pediatric Dosing...") |
Ostermayer (talk | contribs) No edit summary |
||
| Line 40: | Line 40: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]][[Category:GI]] | ||
Revision as of 21:01, 11 May 2016
Administration
- Type: Octapeptide
- Dosage Forms:
- Routes of Administration: IV, IM
- Common Trade Names: Sandostatin, Sandostatin LAR
Adult Dosing
Pediatric Dosing
Special Populations
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
A peptide that mimics endogenous somatostatin. Somatostatin is released by the pancreas, pyloric antrum, and duodenum and inhibits growth hormone, gastrin, Vasoactive intestinal peptide (VIP), gastrin, serotonin, and decreases Insulin like growth factor-1 (IGF-1) and decreases splanchnic blood flow.